SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla gains on completing acquisition of 100% stake in Inzpera Healthsciences

05 Dec 2025 Evaluate

Cipla is currently trading at Rs. 1524.60, up by 3.40 points or 0.22% from its previous closing of Rs. 1521.20 on the BSE.

The scrip opened at Rs. 1523.35 and has touched a high and low of Rs. 1527.00 and Rs. 1513.75 respectively. So far 16662 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1672.20 on 23-Oct-2025 and a 52 week low of Rs. 1310.05 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 1536.20 and Rs. 1495.95 respectively. The current market cap of the company is Rs. 123294.16 crore.

The promoters holding in the company stood at 29.21%, while Institutions and Non-Institutions held 54.79% and 16.00% respectively.

Cipla has completed acquisition of 100% stake in Inzpera Healthsciences (Inzpera) on December 04, 2025. Accordingly, Inzpera has now become a wholly owned subsidiary of the Company.

The acquisition is a strategic move aimed at combining Inzpera’s extensive portfolio of paediatric pharmaceutical and wellness products with the company’s strong distribution network and operational capabilities to drive growth and scalability. Earlier, the company had entered into definitive agreements to acquire 100% stake in Inzpera Healthsciences.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.





Cipla Share Price

1305.85 70.85 (5.74%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×